Community-based Neuroendocrine Tumor (NET) Research Study
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Registration Number
- NCT02730104
- Lead Sponsor
- Ipsen
- Brief Summary
The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot. This is an observational study therefore all data collected will be in accordance with the routine practice of physicians.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Histologically confirmed locally advanced or metastatic, well-differentiated neuroendocrine tumor (NET) of the small bowel, stomach, colon/rectum, or pancreas (low or intermediate grade; i.e. G1 or G2)
- Treatment with lanreotide depot (Somatostatin Analogue-naïve patients and patients with prior treatment with octreotide long-acting repeatable (LAR) are permitted)
- Radiographically measurable disease
- Has signed the most recent written Patient Informed Consent Form
- Known hypersensitivity to lanreotide
- Poorly differentiated or high grade carcinoma, or patients with neuroendocrine tumors not of lung or thymic origin
- Patients who have previously initiated treatment with lanreotide depot prior to the start of the study cannot have progressed between lanreotide initiation and study entry
- Significant history of uncontrolled cardiac disease (ie, myocardial infarction within 6 months prior to enrollment or has congestive heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to disease progression From first date of lanreotide to up to 24 months (approximately) after the last patient is randomised Time to disease progression will be defined as the time from the first date of lanreotide, which may have occurred prior to study entry, to the date of first documented disease progression or the date of tumor-related death. In a living patient with no documented disease progression, or if the patient is lost to follow-up, disease progression will be censored at the date of the last evaluable scan. Patients who start a new treatment before they progress will be censored as of the date of last scan. Disease progression is defined for this study as both clinical dimensions of progression in conjunction with a treatment change.
- Secondary Outcome Measures
Name Time Method Overall survival From first date of lanreotide to up to 24 months (approximately) after the last patient is randomised Overall survival will be defined as the time from the first date of lanreotide, which may have occurred prior to study entry, to the date of death due to any cause or the last date the patient was known to be alive.
Adverse events Duration of the study, up to 24 months Change in flushing and diarrhea Baseline, month 6, 12, 18, 24, end of treatment visit (+/-28 days from patients off treatment) To be assessed as present or not, and if present, as mild, moderate, or severe. At subsequent visits, it should be noted whether these symptoms are better, worse, or the same as at previous visit.
Patient satisfaction with treatment Month 6, 12, 18, 24, end of treatment visit (+/-28 days from patients off treatment) Treatment Satisfaction Questionnaire for Medication (TQSM-9)
Trial Locations
- Locations (12)
Texas Oncology - Denton South
🇺🇸Denton, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
🇺🇸Dallas, Texas, United States
Illinois Cancer Specialists
🇺🇸Arlington Heights, Illinois, United States
Oncology Hematology Care, Inc.
🇺🇸Cincinnati, Ohio, United States
Rocky Mountain Cancer Centers
🇺🇸Denver, Colorado, United States
Arizona Oncology Associates
🇺🇸Sedona, Arizona, United States
Texas Oncology - Dallas Presbyterian Hospital
🇺🇸Dallas, Texas, United States
Texas Oncology - Beaumont, Mamie McFaddin Ward Cancer Center
🇺🇸Beaumont, Texas, United States
Texas Oncology-Tyler
🇺🇸Tyler, Texas, United States
Texas Oncology - Deke Slayton Cancer Center
🇺🇸Webster, Texas, United States
Yakima Valley Memorial Hospital/North Star Lodge
🇺🇸Yakima, Washington, United States
Texas Oncology
🇺🇸Houston, Texas, United States